DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...

Mizuho raised the firm’s price target on DexCom (DXCM) to $78 from $75 and keeps an Outperform rating on the shares. The firm ...

Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...

Investors encouraged to join DexCom class action lawsuit. Allegations include unapproved design changes to G6/G7 glucose ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Buy rating on Dexcom, with a price target of $84.00. The company’s shares closed yesterday at $66.96.

All four Irish provinces are back in action this week across the Investec Champions and Challenge Cup pool stages. Here's everything you need to know ahead of this weekend's games.

Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $2,028.09 today based on a price of $65.71 for DXCM at the time of writing.

Connacht Rugby and the IRFU have announced that Dexcom Stadium will host the Guinness Women's Six Nations fixture between ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US ...

Join us on Dec. 10 for a live webinar on Trend Detection, now upgraded with state-court insight and enhanced alerting to help ...